Company Description
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally.
The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development.
Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers.
Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.
| Country | United States |
| Founded | 1976 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Kara Cannon |
Contact Details
Address: 21 Executive Blvd Farmingdale, New York 11735 United States | |
| Phone | 631 755 5500 |
| Website | enzo.com |
Stock Details
| Ticker Symbol | ENZ |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0000316253 |
| CUSIP Number | 294100102 |
| ISIN Number | US2941001024 |
| Employer ID | 13-2866202 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Kara Cannon | Chief Executive Officer and Director |
| Patricia Eckert CPA | Chief Financial Officer |
| Brian J. Fisher | General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 16, 2025 | 8-K | Current Report |
| Jan 15, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 10-Q | Quarterly Report |
| Nov 29, 2024 | ARS | Filing |
| Nov 27, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 25, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 10-K | Annual Report |
| Sep 24, 2024 | 8-K | Current Report |